Abbvie
5 products tracked · names used in filings: Abbvie, Abbvie Inc, AbbVie Limited
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 25 Sep 2026🇺🇸 FDA approval
FDA approves Juvmo (tavapadon), a new medicine
Wed 15 Jul 2026🇪🇺 EU approval (EC decision)
Boey (trenibotulinumtoxinE) approved in the EU
Marketing authorisation to AbbVie Limited; Additional monitoring · source
Wed 27 May 2026🇺🇸 FDA approval
FDA approves Decnupaz (pivekimab sunirine-pvzy), a new medicine
Abbvie Inc; BLA761460; New biologic, Priority review; vial · source
Thu 21 May 2026🇪🇺 CHMP positive opinion
Boey (trenibotulinumtoxinE): CHMP positive opinion
AbbVie Limited; Additional monitoring · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | Cokiera | Application withdrawn | |
| 🇺🇸 | Juvmo tavapadon | Approved | 2026-09-25 |
| 🇪🇺 | Boey trenibotulinumtoxinE | Authorised | 2026-07-15 |
| 🇺🇸 | Decnupaz pivekimab sunirine-pvzy | Approved | 2026-05-27 |
| 🇪🇺 | Exviera dasabuvir | Withdrawn | 2015-01-14 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.